Literature DB >> 17626519

Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease.

S Wojcik1, W K Engel, V Askanas.   

Abstract

Nogo (RTN4) belongs to the reticulon (RTN) family of integral membrane proteins. RTN4A (Nogo-A), RTN4B (Nogo-B) and RTN4C (Nogo-C) are isoforms of RTN4. In the gastrocnemius muscle of transgenic mice bearing an SOD1 mutation ("ALS model"), increased Nogo-A mRNA and protein was reported, and similar changes were reported in muscle biopsies of patients with amyotrophic lateral sclerosis (ALS) but not with peripheral neuropathy or primary muscle diseases, leading to the proposal that Nogo-A in skeletal muscle is a new specific molecular marker of ALS. Here we report, based on studies of muscle biopsies from patients with ALS, peripheral neuropathies, polymyositis, dermatomyositis and morphologically nonspecific myopathies that, in addition of strong Nogo-A immunoreactivity within apparently-denervated small angular fibers in ALS and peripheral neuropathies, Nogo-A was strongly immunoreactive within desmin-positive regenerating muscle fibers in various myopathies, and its expression on immunoblots was increased in all those neuromuscular diseases. In conclusion, we have found that the presence of Nogo-A in diseased human muscle biopsies is not limited to ALS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17626519

Source DB:  PubMed          Journal:  Acta Myol        ISSN: 1128-2460


  9 in total

Review 1.  Mechanisms controlling neuromuscular junction stability.

Authors:  Evelyne Bloch-Gallego
Journal:  Cell Mol Life Sci       Date:  2014-10-31       Impact factor: 9.261

Review 2.  Biomarkers in amyotrophic lateral sclerosis: facts and future horizons.

Authors:  Pierre-François Pradat; Michel Dib
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

3.  Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients.

Authors:  Noam Y Harel; Merit E Cudkowicz; Robert H Brown; Stephen M Strittmatter
Journal:  Biomarkers       Date:  2009-09       Impact factor: 2.658

Review 4.  New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis.

Authors:  Xueping Chen; Hui-Fang Shang
Journal:  Transl Neurodegener       Date:  2015-09-30       Impact factor: 8.014

Review 5.  The role of reticulons in neurodegenerative diseases.

Authors:  Valerio Chiurchiù; Mauro Maccarrone; Antonio Orlacchio
Journal:  Neuromolecular Med       Date:  2013-11-12       Impact factor: 3.843

6.  Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.

Authors:  Vincent Meininger; Pierre-François Pradat; Andrea Corse; Safa Al-Sarraj; Benjamin Rix Brooks; James B Caress; Merit Cudkowicz; Stephen J Kolb; Dale Lange; P Nigel Leigh; Thomas Meyer; Stefano Milleri; Karen E Morrison; Richard W Orrell; Gary Peters; Jeffrey D Rothstein; Jeremy Shefner; Arseniy Lavrov; Nicola Williams; Phil Overend; Jeffrey Price; Stewart Bates; Jonathan Bullman; David Krull; Alienor Berges; Bams Abila; Guy Meno-Tetang; Jens Wurthner
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

Review 7.  The reticulons: a family of proteins with diverse functions.

Authors:  Yvonne S Yang; Stephen M Strittmatter
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

Review 8.  Nogo-A and Nogo-66 receptor in amyotrophic lateral sclerosis.

Authors:  Felicia Yu Hsuan Teng; Bor Luen Tang
Journal:  J Cell Mol Med       Date:  2008-04-15       Impact factor: 5.310

Review 9.  Synaptic Failure: Focus in an Integrative View of ALS.

Authors:  Caty Casas; Raquel Manzano; Rita Vaz; Rosario Osta; Dora Brites
Journal:  Brain Plast       Date:  2016-06-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.